Contraception News and Research

Latest Contraception News and Research

FDA's labeling of Ella as 'Emergency Contraceptive' misleading, says FRC

Today the Food and Drug Administration (FDA) approved Ella, a drug that can cause abortions but is misleadingly labeled as a more effective "Emergency Contraceptive."

16 Aug 2010

FDA approves ellaOne for emergency contraception

HRA Pharma announced today that the US Food and Drug Administration (FDA) granted approval for ella(R) (ulipristal acetate) as a prescription-only emergency contraceptive indicated for use within 120 hours (five days) of unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.

16 Aug 2010

Mass. docs will soon track patients who abuse prescription drugs; Wis. Catholic Church employees now eligible for birth control

The Boston Globe: "With a few computer keystrokes, Massachusetts physicians will soon be able to identify patients who travel from clinic to clinic in pursuit of potent prescription drugs that feed lethal addictions. State health regulators yesterday unanimously approved the new detection system designed to stop 'doctor shopping' by addicted patients who try to dupe doctors into prescribing narcotics. The practice, specialists said, has fueled a surge in drug-related deaths in Massachusetts" (Smith, 8/12).

13 Aug 2010

Education and screening of pregnant women recommended for prevention of Fetal Alcohol Spectrum Disorder

Featured in the August edition of the Journal of Obstetrics and Gynaecology Canada is a new consensus clinical practice guideline which recommends that screening for alcohol consumption be done periodically for all pregnant women and women of child-bearing age.

13 Aug 2010

Oral sex becomes common activity among young women: Study

University of Alberta researcher Brea Malacad says results from a study on oral sex indicate there is little doubt that oral sex is becoming a more common activity for young women. Study results show the act has become a fundamental part of what Malacad calls the "sexual revolution of the 21st century". And she concludes that researchers, sex educators and marketers of safer-sex paraphernalia need to catch up with the trend.

12 Aug 2010

Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch

Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced study initiation and dosing of the first patient in the Company's pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. AG200-15 is designed to effectively deliver a low dose of estrogen in combination with levonorgestrel. The patch is applied once weekly for three weeks followed by a patch-free week.

11 Aug 2010

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

PregLem, the Swiss specialty biopharmaceutical company focused on women's reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

11 Aug 2010

Norwegian cervical screening program begins reimbursing for liquid-based cytology

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that on July 1, 2010, the Norwegian cervical screening program began reimbursing for liquid-based cytology (LBC).

6 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

MOM Project increases access to maternal health care services for internally displaced woman

A community-based maternal health delivery strategy known as the MOM Project dramatically increased access to maternal health care services for internally displaced woman in eastern Burma, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health. Among the findings, the study showed a ten-fold increase in the proportion of women assisted at delivery by workers skilled in providing emergency obstetric care, including preventing and treating hemorrhage, injectable antibiotics and anticonvulsants, and community-based blood transfusion.

4 Aug 2010

World Congress on Fertility and Sterility to take place 12-16 September in Munich, Germany

The World Congress on Fertility and Sterility takes place every 3 years. It is the most important international congress in this fast moving field. The 20th congress will take place in Munich, Germany, from 12-16 September, 2010, just a few days before the start of the famous Oktoberfest.

30 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Report urges multi-disciplinary research approach to help HIV-positive women stay healthy

A report issued by the Program on International Health and Human Rights at the Harvard School of Public Health proposes a new research agenda to address the sexual and reproductive health and rights of HIV-positive women.

14 Jul 2010

Fear of having something in uterus deters teen girls from using intrauterine devices for birth control

Very few teenage girls in the United States use intrauterine devices for birth control, even though studies show they are safe, effective and extremely low-maintenance, according to researchers at Lucile Packard Children's Hospital and the Stanford School of Medicine.

9 Jul 2010

Hormonal contraceptives are less effective for birth control in overweight or obese women: Study

As obesity continues to be a worldwide health risk, one of its "side effects" could include less effective birth control for overweight and obese women who use hormonal contraceptives.

9 Jul 2010

Pregnant teenagers at higher risk of preterm delivery

Pregnant women aged 14-17 years are at higher risk of preterm birth and of having a child with low-birth-weight, especially if they are having their second child. Researchers writing in the open access journal BMC Pregnancy and Childbirth demonstrate this association and call for better health education and the promotion of contraception after a teenager has given birth for the first time.

9 Jul 2010

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Hologic, Inc., a leading women's healthcare company, today announced that final data analysis from the first large-scale independent evaluation of clinical performance of Cervista HPV HR compared to Hybrid Capture 2, were presented in Montreal, Canada, at the 26th International Papillomavirus Conference. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus types.

8 Jul 2010

Hologic enters definitive agreement to acquire Sentinelle Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that it has entered into a definitive agreement to acquire Sentinelle Medical Inc., a leading provider of Magnetic Resonance Imaging (MRI) breast coils, tables and visualization software.

From Hologic, Inc. 7 Jul 2010

Some state insurance commissioners push back on Fed premium rate reviews

Politico: Some state insurance commissioners are not happy with a proposal that would give the federal government the authority to centralize premium rate reviews of health insurance.

7 Jul 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

Contraception News and Research

Latest Contraception News and Research

FDA's labeling of Ella as 'Emergency Contraceptive' misleading, says FRC

FDA approves ellaOne for emergency contraception

Mass. docs will soon track patients who abuse prescription drugs; Wis. Catholic Church employees now eligible for birth control

Education and screening of pregnant women recommended for prevention of Fetal Alcohol Spectrum Disorder

Oral sex becomes common activity among young women: Study

Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

Norwegian cervical screening program begins reimbursing for liquid-based cytology

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

MOM Project increases access to maternal health care services for internally displaced woman

World Congress on Fertility and Sterility to take place 12-16 September in Munich, Germany

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Report urges multi-disciplinary research approach to help HIV-positive women stay healthy

Fear of having something in uterus deters teen girls from using intrauterine devices for birth control

Hormonal contraceptives are less effective for birth control in overweight or obese women: Study

Pregnant teenagers at higher risk of preterm delivery

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Hologic enters definitive agreement to acquire Sentinelle Medical

Some state insurance commissioners push back on Fed premium rate reviews

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Contraception News and Research

Latest Contraception News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in